参考文献
［1］朱晓丽，谷祥富，路会侠，et al.糖尿病患者自我管理现状及教育管理模式展望[J].临床护理杂志，2021，20（2）： 70-73.
［2］中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020版）[J].中华糖尿病杂志，2021，13（4）： 315-409.
［3］Evert AB,Dennison M,Gardner CD,et al.Nutritiontherapy for adults with diabetes or prediabetes: aconsensus report[J].Diabetes Care,2019,42(5): 731-754.
［4］Brath H，Kaser S，Tatschl C，et al.Smoking,alkohol und diabetes mellitus（update 2019）[J].Wien klin wochenschr，2019,131(1): 67-70.
［5］中华医学会糖尿病学分会.中国血糖监测临床应用指南（2021年版）[J].中华糖尿病杂志，2021，13（10）： 936-948.
［6］刘蔚，纪立农.从循证证据看扫描式葡萄糖监测技术的应用[J].中华糖尿病志，2018，10（10）： 637-639.
［7］蔡玲莉，周健，贾伟平.瞬感扫描式葡萄糖监测系统的临床研究进展[J].中华内科杂志.2018，57（11）： 858-861.
［8］李红典，李明轩，白薇，等.参芪降糖颗粒联合二甲双胍治疗2型糖尿病有效性及安全性的Meta分析[J].世界中西医结合杂志，2020，15（9）：1630-1637.
［9］Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week,double-blind,phase 3a,randomized trial[J].Diabetes,Obesity and Metabolism,2021,23(2)
［10］Heerspink H,Stefánsson B V,Correa-Rotter R,et al.Dapagliflozin in Patients with Chronic Kidney Disease[J].N Engl J Med,2020,383(15): 1436-1446.(https://www.daowen.com)
［11］Gerstein H C,Colhoun H M,Dagenais G R,et al.Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind,randomised placebo-controlled trial[J].Lancet,2019,394(10193): 121-130.
［12］Xu Y,Wang L,He J,et al.Prevalence and control of diabetes in Chinese adults[J].JAMA,2013,310(9): 948-959.
［13］Li Y,Teng D,Shi X,et al.Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J].bmj,2020,369:m997.
［14］WENG J,ZHOU Z,GUO L,et al.Incidence of type 1 diabetes in China,2010-13: population-based study[J].bmj,2018,360: j5295.
［15］朱大龙，起家军，苏青，等.中国成人2型糖尿病患者糖化血红蛋白控制目标及达标策略专家共识[J].中华内分泌代谢杂志，2020（01）： 14-24.
［16］Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes 2021[J].Diabetes Care,2021,44(Suppl 1): S111-S124.
［17］Perkovic V,Jardine M J,Neal B,et al.Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy[J].N Engl J Med,2019,380(24): 2295-2306.
［18］Yamada T,Shojima N,NOMA H,et al.Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials[J].Diabetes Obes Metab,2018,20(7):1755-1761.
［19］Maruyama T,Tanaka S,Shimada A,et al.Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus[J].J Clin Endocrinol Metab,2008,93(6): 2115-2121.
（周敏、许玄、许文琼、钟树妹、谷丽娟、刘建萍、黄秋兰、刘爽）